IP Library › Granted Patent US 11,786,441

Granted Patent B2

US 11,786,441 · App. 16/024,825 · Granted Oct 17, 2023

Glass articles with low-friction coatings

Inventors: Andrei Gennadyevich Fadeev (Elmira, NY); Theresa Chang (Painted Post, NY); Dana Craig Bookbinder (Corning, NY); Santona Pal (Painted Post, NY); Chandan Kumar Saha (Franklin, MI); Steven Edward DeMartino (Painted Post, NY); Christopher Lee Timmons (Big Flats, NY); John Stephen Peanasky (Big Flats, NY)

Assignee: CORNING INCORPORATED

A61J1/1468 B65D23/0821 C03C17/005 C03C17/30 C03C17/32 C03C17/42 C03C21/002 C03C2217/78 Y10T428/1321 Y10T428/24926 Y10T428/265

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,786,441
App. No.: 16/024,825
Granted: Oct 17, 2023
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may Include a glass body formed from borosilicate glass that meets Type 1 criteria according to USP <660> or alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating comprising a polymer may be positioned on a portion of the exterior surface. A coefficient of friction of an abraded area of the portion of the exterior surface with the low-friction coating may be less than 0.7 after exposure to a temperature of 260° C. for 30 minutes and abrasion under a load of at least 10 N and does not have observable damage. A retained strength of the coated glass article in horizontal compression does not decrease by more than 20% after the temperature exposure and the abrasion.

Claims (150)

1. A coated glass pharmaceutical package comprising:

a glass body formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard;

the glass body having an interior surface and an exterior surface and a wall extending therebetween; and

a low-friction coating bonded to at least a portion of the exterior surface but not on any portion of the interior surface, wherein:

the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating has a coefficient of friction of less than or equal to 0.7, the coefficient of friction is a maximum coefficient of friction measured relative to a second coated glass pharmaceutical package in a vial-on-vial testing jig under a normal load of 30 N, the second coated glass pharmaceutical package formed from the same glass composition and comprising the low-friction coating on at least a portion of a second exterior outer surface of the second coated glass pharmaceutical package and subjected to the same environmental conditions prior to measurement of the coefficient of friction;

the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a second normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes; and

the low-friction coating comprises:

a polymer; and

a coupling agent.

2. The coated glass pharmaceutical package of claim 1 , the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a second normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes.

3. The coated glass pharmaceutical package of claim 1 , wherein the polymer is selected from a group consisting of polyimides, polybenzimidazoles, polysulfones, polyetheretheketones, polyetherimides, polyamides, polyphenyls, polybenzothiazoles, polybenzoxazoles, polybisthiazoles, polyaromatic heterocyclic polymers, fluoropolymers, silicone resins and silsesquioxane-based polymers.

4. The coated glass pharmaceutical package of claim 3 , wherein the coupling agent comprises an inorganic material.

5. The coated glass pharmaceutical package of claim 3 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

6. The coated glass pharmaceutical package of claim 3 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a second normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

7. The coated glass pharmaceutical package of claim 3 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a second normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

8. The coated glass pharmaceutical package of claim 3 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of about 260° C. for 30 minutes.

9. The coated glass pharmaceutical package of claim 3 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of about 260° C. for 30 minutes.

10. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polyimide.

11. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a fluoropolymer.

12. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a silicone resin.

13. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polybenzimidazole.

14. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polysulfone.

15. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polyetheretheketone.

16. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polyetherimide.

17. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polyamide.

18. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polyphenyl.

19. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polybenzothiazole.

20. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polybenzoxazole.

21. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polybisthiazole.

22. The coated glass pharmaceutical package of claim 1 , wherein the polymer is a polyaromatic heterocyclic polymer.

23. The coated glass pharmaceutical package of claim 1 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under the second normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

24. The coated glass pharmaceutical package of claim 1 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a second normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

25. The coated glass pharmaceutical package of claim 1 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a second normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of about 260° C. for 30 minutes.

26. The coated glass pharmaceutical package of claim 1 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a second normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of about 260° C. for 30 minutes.

27. The coated glass pharmaceutical package of claim 1 , wherein the coupling agent comprises an inorganic material.

28. The coated glass pharmaceutical package of claim 1 , wherein the coupling agent is in direct contact with the exterior surface and the polymer is in direct contact with the coupling agent.

29. The coated glass pharmaceutical package of claim 1 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

30. A coated glass article comprising:

the glass body having an interior surface and an exterior surface and a wall extending therebetween; and

a low-friction coating positioned on at least a portion of the exterior surface but not on any portion of the interior surface, the low-friction coating comprising a polymer, wherein:

the polymer is selected from a group consisting of polyimides, polybenzimidazoles, polysulfones, polyetheretheketones, polyetherimides, polyamides, polybenzothiazoles, polybenzoxazoles, polybisthiazoles, polyaromatic heterocyclic polymers, fluoropolymers, silicone resins, and silsesquioxane-based polymers;

a thickness of the low-friction coating is less than or equal to 1 μm;

a coefficient of friction of an abraded area of the portion of the exterior surface with the low-friction coating is less than 0.7 after exposure to a temperature of 260° C. for 30 minutes and abrasion under a load of 10 N and does not have observable damage; and

a retained strength of the coated glass article in horizontal compression does not decrease by more than about 20% after exposure to the temperature of 260° C. for 30 minutes and abrasion under a load of 10 N.

31. The coated glass article of claim 30 , wherein:

the coefficient of friction of the abraded area of the portion of the exterior surface with the low-friction coating is less than 0.7 after exposure to a temperature of 260° C. for 30 minutes and abrasion under a load of 20 N and does not have observable damage; and

the retained strength of the coated glass article in horizontal compression does not decrease by more than about 20% after exposure to the temperature of 260° C. for 30 minutes and abrasion under a load of 20 N.

32. The coated glass article of claim 30 , wherein the polymer is a polyimide.

33. The coated glass article of claim 30 , wherein the polymer is a fluoropolymer.

34. The coated glass article of claim 30 , wherein the polymer is a silicone resin.

35. The coated glass article of claim 30 , wherein the polymer is a polybenzimidazole.

36. The coated glass article of claim 30 , wherein the polymer is a polysulfone.

37. The coated glass article of claim 30 , wherein the polymer is a polyetheretheketone.

38. The coated glass article of claim 30 , wherein the polymer is a polyetherimide.

39. The coated glass article of claim 30 , wherein the polymer is a polyamide.

40. The coated glass article of claim 30 , wherein the polymer is a polybenzothiazole.

41. The coated glass article of claim 30 , wherein the polymer is a polybenzoxazole.

42. The coated glass article of claim 30 , wherein the polymer is a polybisthiazole.

43. The coated glass article of claim 30 , wherein the polymer is a polyaromatic heterocyclic polymer.

44. The coated glass article of claim 30 , wherein:

the coefficient of friction of the abraded area of the portion of the exterior surface with the low-friction coating is less than 0.7 after exposure to a temperature of at least about 300° C. for 30 minutes and abrasion under a 10 N load and does not have observable damage; and

the retained strength of the coated glass article in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 300° C. for 30 minutes and abrasion under a 10 N load.

45. The coated glass article of claim 30 , wherein:

46. The coated glass article of claim 30 , wherein

the coefficient of friction of the abraded area of the portion of the exterior surface with the low-friction coating is less than 0.7 after exposure to a temperature of from about 260° C. to about 400° C. for 30 minutes and abrasion under a 10 N load and does not have observable damage; and

the retained strength of the coated glass article in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 260° C. for 30 minutes and abrasion under a 10 N load.

47. The coated glass article of claim 30 , wherein:

48. The coated glass article of claim 30 further comprising a coupling agent, wherein the coupling agent comprises an inorganic material.

49. The coated glass article of claim 48 , wherein the coupling agent is in direct contact with the exterior surface and the polymer is in direct contact with the coupling agent.

50. The coated glass article of claim 48 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

51. The coated glass article of claim 30 further comprising a coupling agent, wherein the coupling agent comprises an inorganic material.

52. The coated glass article of claim 51 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

53. The coated glass article of claim 30 , wherein

54. The coated glass article of claim 30 , wherein:

55. The coated glass article of claim 30 , wherein

56. The coated glass article of claim 30 , wherein:

57. A coated glass pharmaceutical package:

the glass body having an interior surface and an exterior surface and a wall extending therebetween; and

a low-friction coating positioned on at least a portion of the exterior surface but not on any portion of the interior surface, the low-friction coating comprising a polymer, wherein a retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of 260° C. for 30 minutes and abrasion under a load of 10 N, and wherein a thickness of the low-friction coating is less than or equal to 1 μm; and

wherein the polymer is selected from a group consisting of polyimides, polybenzimidazoles, polysulfones, polyetheretheketones, polyetherimides, polyamides, polybenzothiazoles, polybenzoxazoles, polybisthiazoles, polyaromatic heterocyclic polymers, fluoropolymers, silicone resins, and silsesquioxane-based polymers.

58. The coated glass pharmaceutical package of claim 57 , wherein a retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of 260° C. for 30 minutes and abrasion under a load of 20 N.

59. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polyimide.

60. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a fluoropolymer.

61. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a silicone resin.

62. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polybenzimidazole.

63. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polysulfone.

64. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polyetheretheketone.

65. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polyetherimide.

66. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polyamide.

67. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polybenzothiazole.

68. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polybenzoxazole.

69. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polybisthiazole.

70. The coated glass pharmaceutical package of claim 57 , wherein the polymer is a polyaromatic heterocyclic polymer.

71. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 300° C. for 30 minutes and abrasion under a 10 N load.

72. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 300° C. for 30 minutes and abrasion under a 20 N load.

73. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 260° C. for 30 minutes and abrasion under a 10 N load.

74. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 260° C. for 30 minutes and abrasion under a 20 N load.

75. The coated glass pharmaceutical package of claim 57 further comprising a coupling agent, wherein the coupling agent comprises an inorganic material.

76. The coated glass pharmaceutical package of claim 75 , wherein the coupling agent is in direct contact with the exterior surface and the polymer is in direct contact with the coupling agent.

77. The coated glass pharmaceutical package of claim 75 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

78. The coated glass pharmaceutical package of claim 57 further comprising a coupling agent, wherein the coupling agent comprises an inorganic material.

79. The coated glass pharmaceutical package of claim 78 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

80. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 300° C. for 30 minutes and abrasion under a 10 N load.

81. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 300° C. for 30 minutes and abrasion under a 20 N load.

82. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 260° C. for 30 minutes and abrasion under a 10 N load.

83. The coated glass pharmaceutical package of claim 57 , wherein the retained strength of the coated glass pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to a temperature of about 260° C. for 30 minutes and abrasion under a 20 N load.

84. A coated glass pharmaceutical package comprising:

a glass body comprising a first surface and a second surface opposite the first surface, wherein the glass body is a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard, the first surface is an exterior surface of the glass container, and the second surface is an interior surface of the glass container; and

a low-friction coating positioned on at least a portion of the first surface of the glass body but not on any portion of the second surface, the low-friction coating comprising a polymer, wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with a second coated glass pharmaceutical package formed from the same glass composition in a vial-on-vial testing jig under a normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes, and wherein a thickness of the low-friction coating is less than or equal to 1 μm; and

85. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with a second coated glass pharmaceutical package formed from the same glass composition in a vial-on-vial testing jig under a normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes.

86. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polyimide.

87. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a fluoropolymer.

88. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a silicone resin.

89. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polybenzimidazole.

90. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polysulfone.

91. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polyetheretheketone.

92. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polyetherimide.

93. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polyamide.

94. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polybenzothiazole.

95. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polybenzoxazole.

96. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polybisthiazole.

97. The coated glass pharmaceutical package of claim 84 , wherein the polymer is a polyaromatic heterocyclic polymer.

98. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

99. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

100. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of about 260° C. for 30 minutes.

101. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with a second coated glass pharmaceutical package formed from the same glass composition in a vial-on-vial testing jig under a normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes.

102. The coated glass pharmaceutical package of claim 84 further comprising a coupling agent, wherein the coupling agent comprises an inorganic material.

103. The coated glass pharmaceutical package of claim 102 , wherein the coupling agent is in direct contact with the exterior surface and the polymer is in direct contact with the coupling agent.

104. The coated glass pharmaceutical package of claim 102 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

105. The coated glass pharmaceutical package of claim 84 further comprising a coupling agent, wherein the coupling agent comprises an inorganic material.

106. The coated glass pharmaceutical package of claim 105 , wherein the coupling agent comprises titanates, zirconates, tin, titanium, tin oxide, or titanium oxide.

107. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

108. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 300° C. for 30 minutes.

109. The coated glass pharmaceutical package of claim 84 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 10 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of about 260° C. for 30 minutes.

110. The coated glass pharmaceutical package of claim 109 , wherein the portion of the exterior surface of the coated glass pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with the second coated glass pharmaceutical package in the vial-on-vial testing jig under a normal load of 20 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of about 260° C. for 30 minutes.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2018

From: FADEEV, ANDREI GENNADYEVICH; CHANG, THERESA; BOOKBINDER, DANA CRAIG; PAL, SANTONA; SAHA, CHANDAN KUMAR; DEMARTINO, STEVEN EDWARD; TIMMONS, CHRISTOPHER LEE; PEANASKY, JOHN STEPHEN

To: CORNING INCORPORATED

Reel/Frame 046247/0574 →

Continuity (5)

Continuation 15374338 · Dec 9, 2016

Continuation 13780754 · Feb 28, 2013

Provisional Application 61665682 · Jun 28, 2012

Provisional Application 61604220 · Feb 28, 2012

Related Publication 20180303708A1 · Oct 25, 2018